Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 5/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751743 | 0.90 | CD274 (0.37) | ERN1PDCD1LG2CD274PDE10ACTSL | |
| SCHEMBL3757999 | 0.90 | PPARG (0.35) | ERN1PDCD1LG2CD274PDE2APDE10A | |
| SCHEMBL3753274 | 0.87 | PDE2A (0.39) | PDCD1LG2CD274PDE2APDE10A | |
| SCHEMBL3754331 | 0.85 | ERN1 (0.42) | ERN1PDCD1LG2CD274 | |
| SCHEMBL3753273 | 0.85 | CTSA (0.37) | ERN1PDCD1LG2CD274PDE2APDE10A | |
| SCHEMBL3749589 | 0.84 | PDCD1LG2 (0.35) | ERN1PDCD1LG2CD274PDE2APDE10A | |
| SCHEMBL3752610 | 0.82 | PDE2A (0.38) | ERN1PDCD1LG2CD274PDE2APDE10A | |
| SCHEMBL3747192 | 0.82 | MPL (0.40) | ERN1PDCD1LG2CD274PDE2APDE10A | |
| SCHEMBL3753385 | 0.82 | HSD11B1 (0.41) | ERN1PDCD1LG2CD274CTSLCTSS | |
| SCHEMBL3757716 | 0.81 | EIF4E (0.39) | CD274PPARGHSD17B14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | ERN1 4268/4885PDCD1LG2 2842/4885CD274 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.